Literature DB >> 21228671

Changing management and survival in patients with stage IV colorectal cancer.

Cameron Platell1, Siobhan Ng, Austin O'bichere, Niall Tebbutt.   

Abstract

BACKGROUND: Patients with metastatic colorectal cancers have poor outcomes. Yet recent developments in the use of chemotherapy and surgery have promised improvements in survival. The aim of this study was to compare the treatment and survival for all patients presenting with stage IV colorectal cancer managed over the last 20 years at a tertiary referral center and to define independent predictors for survival.
METHODS: A cohort of patients with stage IV colorectal cancer treated from 1989 through 1995 served as a historical control for comparison with prospective cohorts treated from 1996 through 2002 or from 2003 through 2009. The Kaplan Meier technique was used to calculate overall survival. The Cox proportional hazards model was used to determine independent predictors of survival.
RESULTS: A total of 313 patients with stage IV colorectal cancer were analyzed. Two-year overall survival was significantly higher in the 2003 to 2009 cohort (40.3%; 95%CI, 28.6-51.8%) than in either the 1989 to 1995 cohort (20.6%, 95%CI, 13.5- 28.6%) or the 1996 to 2002 cohort (19.3%; 95%CI, 12.8-26.9%). Significant independent predictors for overall survival included surgical resection with anastomosis (hazard ratio, 0.507; 95%CI, 0.371-0.692), surgical resection with stoma (0.578; 0.401-0.833), ASA score 3 (1.493; 1.150-1.941) or score 4 (2.532; 1.505-4.258), receiving palliative chemotherapy (0.64; 0.457-0.885), and receiving palliative radiotherapy (0.543; 0.352-0.835).
CONCLUSIONS: In this analysis of overall survival for patients with stage IV colorectal cancer treated from 1989 through 2009, significant improvements were noted only in the last 7 years. Improvements may be related to more widespread use of palliative chemotherapy, newer chemotherapy agents, surgical excision of the primary tumor, and lower postoperative mortality.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21228671     DOI: 10.1007/DCR.0b013e3182023bb0

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  12 in total

1.  Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.

Authors:  Titto Augustine; Radhashree Maitra; Jinghang Zhang; Jay Nayak; Sanjay Goel
Journal:  Invest New Drugs       Date:  2019-01-05       Impact factor: 3.850

2.  Primary Tumor Resection in Patients with Incurable Localized or Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis.

Authors:  Constantinos Simillis; Eliana Kalakouti; Thalia Afxentiou; Christos Kontovounisios; Jason J Smith; David Cunningham; Michel Adamina; Paris P Tekkis
Journal:  World J Surg       Date:  2019-07       Impact factor: 3.352

3.  Prognostic scoring system for stage IV colorectal cancer: is the AJCC sub-classification of stage IV colorectal cancer appropriate?

Authors:  Hirotoshi Kobayashi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2012-06-13       Impact factor: 3.402

Review 4.  Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review.

Authors:  Louis de Mestier; Gilles Manceau; Cindy Neuzillet; Jean Baptiste Bachet; Jean Philippe Spano; Reza Kianmanesh; Jean Christophe Vaillant; Olivier Bouché; Laurent Hannoun; Mehdi Karoui
Journal:  World J Gastrointest Oncol       Date:  2014-06-15

5.  Influence of hospital type on survival in stage IV colorectal cancer.

Authors:  Nobuaki Hoshino; Suguru Hasegawa; Koya Hida; Kenji Kawada; Ryosuke Okamura; Madoka Hamada; Yoshinori Munemoto; Yoshiharu Sakai; Masahiko Watanabe
Journal:  Int J Colorectal Dis       Date:  2016-06-03       Impact factor: 2.571

6.  In vivo time-course imaging of tumor angiogenesis in colorectal liver metastases in the same living mice using two-photon laser scanning microscopy.

Authors:  Koji Tanaka; Yuhki Morimoto; Yuji Toiyama; Kohei Matsushita; Mikio Kawamura; Yuhki Koike; Yoshinaga Okugawa; Yasuhiro Inoue; Keiichi Uchida; Toshimitsu Araki; Akira Mizoguchi; Masato Kusunoki
Journal:  J Oncol       Date:  2011-11-03       Impact factor: 4.375

7.  High Rab27A expression indicates favorable prognosis in CRC.

Authors:  Chuanbing Shi; Xiaojun Yang; Yijiang Ni; Ning Hou; Li Xu; Feng Zhan; Huijun Zhu; Lin Xiong; Pingsheng Chen
Journal:  Diagn Pathol       Date:  2015-06-13       Impact factor: 2.644

8.  Primary tumor location as a predictor of the benefit of palliative resection for colorectal cancer with unresectable metastasis.

Authors:  Rong-Xin Zhang; Wen-Juan Ma; Yu-Ting Gu; Tian-Qi Zhang; Zhi-Mei Huang; Zhen-Hai Lu; Yang-Kui Gu
Journal:  World J Surg Oncol       Date:  2017-07-27       Impact factor: 2.754

9.  Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review.

Authors:  Amartej Merla; Sanjay Goel
Journal:  Chemother Res Pract       Date:  2012-10-14

10.  Lymph node status as a prognostic factor after palliative resection of primary tumor for patients with metastatic colorectal cancer.

Authors:  Qingguo Li; Changjian Wang; Yaqi Li; Xinxiang Li; Ye Xu; Guoxiang Cai; Peng Lian; Sanjun Cai
Journal:  Oncotarget       Date:  2017-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.